By: Mwangi Maina, Bashir Mbuthia, Charles Adinda, Carolyne Kubwa, Margaret Wanjiru, Alfred Onyango, Amina Wako, Mary Wambui, Lucy Mumbi, Ragow Khamis Musa, Farhiya Hussein, Maureen Kinyanjui, Erick Kariuki, Rachael Mutabasi
A groundbreaking clinical trial has found that daraxonrasib nearly doubled survival time for patients with advanced pancreatic cancer, raising hopes for a major breakthrough in the treatment of one of the world's deadliest cancers.













